ArticleAnnals of thoracic surgery short reports2026
Thoracic Duct-to-Azygous Vein Lymphovenous Anastomosis for Lymphatic Decompression: Initial Experience and Early Outcomes.
Article in Annals of thoracic surgery short reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thoracic duct obstruction can cause devastating lymphatic complications, and definitive treatments remain lacking. This investigation evaluated our initial experience and early outcomes using a surgically created thoracic duct-to-azygous vein lymphovenous anastomosis (TDA-LVA) to provide lymphatic decompression in critically ill neonates and infants with thoracic duct obstruction. Methods: All children who underwent TDA-LVA creation at the Children's Hospital of Philadelphia between December 2019 and January 2024 were retrospectively reviewed. Preoperative and postoperative clinical characteristics were compared among all patients. Primary end points of analysis included survival to discharge and at last follow-up. Results: Eight children (median weight, 4.5 kg; interquartile range [IQR], 3.5-5.0 kg) underwent successful TDA-LVA creation. All procedures were tolerated very well. One patient (1 of 8 [12.5%]) required chest washout on postoperative day (POD) 7, and 1 TDA-LVA was unsuccessfully revised on POD 21. The median hospital length of stay after TDA-LVA creation was 138 days (IQR, 64-241 days). Overall, 6 of 8 patients (75.0%) survived to hospital discharge, all of which (6 of 6 [100.0%]) remained alive at a median follow-up of 165 days (IQR, 18-521 days) after discharge. Postoperative TDA-LVA patency was confirmed with conventional lymphangiography in 5 of 8 patients (62.5%), and up to POD 70. Conclusions: A TDA-LVA can restore lymphatic fluid drainage into the systemic venous circulation and remain patent for >2 months in carefully selected patients with thoracic duct obstruction. Further investigations are needed to determine the long-term durability and potential impact on overall quality of life and survival in children with complex lymphatic disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.